The 4 Wall Street analysts covering Shoulder Innovations, Inc. hold a median 12-month price target of $26 — +17.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Shoulder Innovations, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (56): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +17.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | UBS | Maintains | Buy | $27 → $28 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $24 → $26 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $19 → $25 |
| 28 July 2026 | UBS | Initiates | Buy | $27 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 8 May 2026 | Piper Sandler | Reiterates | Overweight | $18 → $19 |
| 8 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 11 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Overweight | — |
| 12 Nov 2025 | Piper Sandler | Reiterates | Overweight | — |
| 9 Sept 2025 | BTIG | Reiterates | Buy | — |
| 26 Aug 2025 | Morgan Stanley | Initiates | Overweight | — |
| 25 Aug 2025 | Goldman Sachs | Initiates | Buy | — |
| 25 Aug 2025 | Jefferies | Initiates | Buy | — |
| 25 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 6 Mar 2023 | Wedbush | Downgrade | Underperform | $4.00 |
| 2 Mar 2023 | Canaccord Genuity | Downgrade | Hold | $25 → $9.00 |
| 2 Mar 2023 | JP Morgan | Downgrade | Underweight | — |
| 1 Mar 2023 | Keefe, Bruyette & Woods | Downgrade | Market Perform | $25 → $16 |
| 9 Jan 2023 | Goldman Sachs | Maintains | Neutral | $35 → $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 15% of US stocks
Cheaper than 29% of US stocks
Cheaper than 88% of US stocks
Higher than 34% of US stocks
Higher than 76% of US stocks
Higher than 89% of US stocks
Higher than 14% of US stocks
Higher than 98% of US stocks
Higher than 27% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Shoulder Innovations, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Shoulder Innovations announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026. Osborne will lead commercial operations for the company, which focuses exclusively on shoulder surgical care.
Why it matters — A leadership change at the commercial helm can influence how Shoulder Innovations executes its sales and market-expansion strategy going forward.
Shoulder Innovations reported second-quarter net revenue of $17.2 million, up 56% from $11 million a year earlier, driven by added surgeons, expanded use among existing customers, and progress on product launches. The company raised its full-year 2026 revenue outlook to $67 million to $69 million from a prior range of $65 million to $68 million.
Why it matters — The revenue growth and raised full-year outlook signal stronger-than-expected performance and momentum for the company's product adoption and expansion.
Shoulder Innovations, Inc. (SI) held its Q2 2026 earnings call, and the full call transcript was published on Seeking Alpha. The transcript covers the company's second-quarter fiscal 2026 results and discussion.
Why it matters — Investors tracking SI can review the earnings call transcript to see management's own discussion of the company's Q2 2026 financial results and outlook.
Shoulder Innovations, Inc. (SI) reported a Q2 loss of $0.46 per share, matching the Zacks Consensus Estimate, compared to a loss of $64.47 per share in the same quarter last year.
Why it matters — The significant year-over-year improvement in per-share loss while meeting analyst expectations may signal progress in the company's financial trajectory.
Shoulder Innovations reported its financial results for the second quarter ended June 30, 2026, disclosing first-half 2026 revenue growth of 60% and raising its full-year outlook.
Why it matters — The raised full-year outlook and strong first-half revenue growth indicate improving financial performance for the company.
The 4 Wall Street analysts covering Shoulder Innovations, Inc. have a median 12-month price target of $26, with estimates ranging from $25 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Shoulder Innovations, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shoulder Innovations, Inc. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Shoulder Innovations, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (56 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +17.9% from the last close, and Ticker Nerd's factor model ranks Shoulder Innovations, Inc. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Shoulder Innovations, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $28 over the next 12 months.
Shoulder Innovations, Inc. returned +80.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Shoulder Innovations, Inc. is a medical technology company that designs, develops, manufactures, and distributes implant replacement systems for shoulder arthroplasty in the United States.
The most recent item we track (PRNewsWire, 10 Aug 2026): "Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer". Shoulder Innovations announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026. Osborne will lead commercial operations for the company, which focuses exclusively on shoulder surgical care.
Shoulder Innovations, Inc. is a medical technology company that designs, develops, manufactures, and distributes implant replacement systems for shoulder arthroplasty in the United States. The company focuses on transforming the shoulder surgical care market by providing advanced shoulder implant solutions and related technologies that support preoperative planning, implant selection, and procedural efficiency. Shoulder Innovations’ portfolio centers on its InSet Glenoid and other implant systems, engineered to enhance fixation, reduce mechanical stress at the bone-implant interface, and improve stability in shoulder joint reconstruction. These products are used by orthopedic surgeons to treat patients requiring shoulder replacement due to degenerative conditions, trauma, or other pathologies. Operating as a commercial-stage enterprise, Shoulder Innovations serves hospitals and surgical centers through specialized sales channels and clinical relationships. Founded in 2009 and headquartered in Grand Rapids, Michigan, the company plays a specialized role within the orthopedic and broader medical device market by concentrating exclusively on shoulder-focused solutions.
CEO Mr. Robert Ball · 56 employees · United States · https://www.shoulderinnovations.com